A detailed history of Sym Financial Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Sym Financial Corp holds 4,405 shares of ABBV stock, worth $1.03 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
4,405
Previous 7,750 43.16%
Holding current value
$1.03 Million
Previous $1.44 Million 29.14%
% of portfolio
0.11%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 03, 2025

SELL
$184.85 - $231.54 $618,323 - $774,501
-3,345 Reduced 43.16%
4,405 $1.02 Million
Q2 2025

Aug 01, 2025

BUY
$170.16 - $206.27 $251,666 - $305,073
1,479 Added 23.58%
7,750 $1.44 Million
Q1 2025

May 06, 2025

BUY
$169.2 - $216.66 $653,958 - $837,390
3,865 Added 160.64%
6,271 $1.31 Million
Q4 2024

Jan 24, 2025

BUY
$164.99 - $203.87 $16,993 - $20,998
103 Added 4.47%
2,406 $427,000
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $31,621 - $38,470
193 Added 9.15%
2,303 $454,000
Q2 2024

Aug 08, 2024

BUY
$154.79 - $180.76 $326,606 - $381,403
2,110 New
2,110 $361,000
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $16,236 - $18,286
118 Added 7.69%
1,652 $256,000
Q3 2023

Oct 27, 2023

BUY
$133.59 - $154.65 $204,927 - $237,233
1,534 New
1,534 $228,000
Q4 2022

Jan 19, 2023

SELL
$138.31 - $165.87 $9,820 - $11,776
-71 Reduced 4.32%
1,572 $0
Q3 2022

Oct 28, 2022

SELL
$134.21 - $153.93 $1,744 - $2,001
-13 Reduced 0.79%
1,643 $221,000
Q2 2022

Jul 19, 2022

BUY
$137.62 - $174.96 $1,789 - $2,274
13 Added 0.79%
1,656 $254,000
Q1 2022

Apr 22, 2022

BUY
$131.98 - $163.75 $216,843 - $269,041
1,643 New
1,643 $266,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Sym Financial Corp Portfolio

Follow Sym Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sym Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sym Financial Corp with notifications on news.